Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
02 03 2020
Historique:
received: 28 05 2019
accepted: 11 12 2019
pubmed: 18 12 2019
medline: 4 11 2020
entrez: 18 12 2019
Statut: ppublish

Résumé

Acute graft-versus-host disease (GVHD) can affect the central nervous system (CNS). The role of microglia in CNS-GVHD remains undefined. In agreement with microglia activation, we found that profound morphological changes and MHC-II and CD80 upregulation occurred upon GVHD induction. RNA sequencing-based analysis of purified microglia obtained from mice with CNS-GVHD revealed TNF upregulation. Selective TNF gene deletion in microglia of Cx3cr1creER Tnffl/- mice reduced MHC-II expression and decreased CNS T cell infiltrates and VCAM-1+ endothelial cells. GVHD increased microglia TGF-β-activated kinase-1 (TAK1) activation and NF-κB/p38 MAPK signaling. Selective Tak1 deletion in microglia using Cx3cr1creER Tak1fl/fl mice resulted in reduced TNF production and microglial MHC-II and improved neurocognitive activity. Pharmacological TAK1 inhibition reduced TNF production and MHC-II expression by microglia, Th1 and Th17 T cell infiltrates, and VCAM-1+ endothelial cells and improved neurocognitive activity, without blocking graft-versus-leukemia effects. Consistent with these findings in mice, we observed increased activation and TNF production of microglia in the CNS of GVHD patients. In summary, we prove a role for microglia in CNS-GVHD, identify the TAK1/TNF/MHC-II axis as a mediator of CNS-GVHD, and provide a TAK1 inhibitor-based approach against GVHD-induced neurotoxicity.

Identifiants

pubmed: 31846439
pii: 130272
doi: 10.1172/JCI130272
pmc: PMC7269577
doi:
pii:

Substances chimiques

CX3C Chemokine Receptor 1 0
Cx3cr1 protein, mouse 0
Histocompatibility Antigens Class II 0
Tumor Necrosis Factor-alpha 0
Vascular Cell Adhesion Molecule-1 0
MAP Kinase Kinase Kinases EC 2.7.11.25
MAP kinase kinase kinase 7 EC 2.7.11.25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1315-1329

Subventions

Organisme : NCI NIH HHS
ID : P01 CA065493
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL056067
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118979
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI034495
Pays : United States

Références

J Exp Med. 2017 Apr 3;214(4):905-917
pubmed: 28330904
J Clin Oncol. 2009 Oct 20;27(30):e147-9
pubmed: 19667266
Br J Haematol. 2006 Jan;132(2):245-7
pubmed: 16398660
J Immunol. 2015 Dec 15;195(12):5795-804
pubmed: 26538394
J Immunol. 2004 Nov 1;173(9):5467-75
pubmed: 15494494
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
J Biol Chem. 1999 Apr 9;274(15):10641-8
pubmed: 10187861
J Neuropathol Exp Neurol. 1993 Sep;52(5):460-70
pubmed: 8103085
Blood. 2018 Apr 19;131(16):1858-1869
pubmed: 29463561
Nat Med. 2010 Dec;16(12):1434-8
pubmed: 21102458
Blood. 2007 Apr 1;109(7):2727-35
pubmed: 17110449
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Blood. 2013 Mar 7;121(10):1906-10
pubmed: 23299314
Nat Med. 2011 Nov 29;18(1):135-42
pubmed: 22127134
J Immunol. 2009 Dec 1;183(11):7169-77
pubmed: 19890056
Blood. 2014 Mar 20;123(12):1967-9
pubmed: 24652969
J Cell Biol. 1991 Jun;113(5):1203-12
pubmed: 1710227
Oncogene. 2007 May 14;26(22):3214-26
pubmed: 17496917
Biol Blood Marrow Transplant. 2019 Sep;25(9):1818-1824
pubmed: 31132454
J Neuroinflammation. 2012 Oct 26;9:245
pubmed: 23102113
Nat Med. 2014 Jun;20(6):648-54
pubmed: 24836575
J Clin Invest. 1999 Aug;104(4):459-67
pubmed: 10449438
Science. 2019 Jan 25;363(6425):
pubmed: 30679343
J Immunol. 2006 Jul 1;177(1):566-73
pubmed: 16785554
J Biol Chem. 2011 Sep 16;286(37):32713-22
pubmed: 21771791
Nat Med. 2005 Mar;11(3):328-34
pubmed: 15735653
Nat Neurosci. 2013 Nov;16(11):1618-26
pubmed: 24077561
Nat Med. 2018 Mar;24(3):282-291
pubmed: 29431743

Auteurs

Nimitha R Mathew (NR)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Janaki M Vinnakota (JM)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.
Faculty of Biology.

Petya Apostolova (P)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.
Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, Medical Center.

Daniel Erny (D)

Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, Medical Center.
Institute for Neuropathology, Faculty of Medicine; and.

Shaimaa Hamarsheh (S)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Geoffroy Andrieux (G)

Institute of Medical Bioinformatics and Systems Medicine (IBSM); Medical Center-University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK), Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jung-Seok Kim (JS)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Kathrin Hanke (K)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Tobias Goldmann (T)

Institute for Neuropathology, Faculty of Medicine; and.

Louise Chappell-Maor (L)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Nadia El-Khawanky (N)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Gabriele Ihorst (G)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Dominik Schmidt (D)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Justus Duyster (J)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Jürgen Finke (J)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.

Thomas Blank (T)

Institute for Neuropathology, Faculty of Medicine; and.

Melanie Boerries (M)

Institute of Medical Bioinformatics and Systems Medicine (IBSM); Medical Center-University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany.
German Cancer Consortium (DKTK), Freiburg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Bruce R Blazar (BR)

Division of Blood and Marrow Transplantation, Masonic Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

Steffen Jung (S)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Marco Prinz (M)

Institute for Neuropathology, Faculty of Medicine; and.
Centre for Integrative Biological Signalling Studies (CIBSS), Signalling Research Centres; and.
Center for Basics in NeuroModulation, Faculty of Medicine; Albert Ludwig University of Freiburg, Freiburg, Germany.

Robert Zeiser (R)

Department of Medicine I, Faculty of Medicine, Medical Center.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center.
Centre for Integrative Biological Signalling Studies (CIBSS), Signalling Research Centres; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH